PHARMACOGENOMICS STUDIES OF HUMAN HYPERTENSION

高血压（HTN）是一种多因素的特征，控制老年人血压（BP）的药物方法并不有效。 因此，大多数患有HTN的美国人没有控制好他们的BP。 在比较不同的抗高血压药物治疗方面存在研究空白。 这项拟议的研究将集中在遗传易感性的交感神经系统的作用，在HTN的一部分，GenHAT（遗传学的高血压相关治疗）的研究。 本研究的主要具体目的是确定多种HTN易感基因在BP对α受体阻滞剂反应的个体间差异中的作用。 该研究将是一个实验性的实验室设计。 可用于分析的样本量为9，081例患者，这些患者被随机分配至a受体阻滞剂多沙唑嗪组。 将探索治疗-基因型相互作用。 据推测，多沙唑嗪的反应将与选定的高血压变异体不同。 遗传学和BP药物治疗的关系的研究可能会指导未来的干预，是特定的患者的HTN的病理，因此，更有效地控制BP。

Hypertension (HTN) is a multifactoral trait, and pharmacological methods to control blood pressure (BP) in older adults have not been effective. As a result, the majority of Americans with HTN do not have their BP under control. A research gap exists in comparing the different antihypertensive pharmacological treatments with each other. The proposed study will focus on the genetic susceptibility of the sympathetic nervous system's role in HTN as part of the GenHAT (Genetics of Hypertension Associated Treatment) study. The primary specific aim for this study is to determine the role of multiple HTN susceptibility genes in interindividual variation in BP response to alpha-blockers. The study will be an experimental laboratory design. The sample size available for analysis is 9,081 patients that were randomly assigned to the a blocker doxazosin. Treatment-genotype interactions will be explored. It is hypothesized that the response to doxazosin will differ with selected hypertensive variants. A study on the relation of genetics and BP pharmacological treatment may direct future intervention that is specific for the pathology of the patient's HTN and, therefore, more effective at controlling BP.